ERIC 2018

The European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) International Meeting 2018, the first of its kind, was held in Barcelona, Spain, from 25–27 October.

Explore the latest CLL news with meeting highlights from the speakers themselves, including biomarkers, opinion on MRD, epigenetics and data to watch out for at ASH 2018.

4:20
Projections from real world evidence of CLL management
Robin Foà
1:50
Current ERIC research in the CLL genomics field
Richard Rosenquist
1:52
ERIC’s first International Meeting and plans for the future
Paolo Ghia
3:08
Resistance mechanisms in CLL
Richard Rosenquist
3:18
Opinion on MRD in CLL: routine use or clinical trials?
Kanti Rai
9:35
Treatment-changing advancements in CLL: BTK, BCL-2, CD20 & CAR T-cells
Kanti Rai
2:49
Genomic discoveries in CLL
Richard Rosenquist
1:44
CLL treatment duration and the role of MRD
Peter Hillmen
0:51
An update on ERIC initiatives
Paolo Ghia
2:13
CLL cell dynamics
Nicholas Chiorazzi
1:00
European Research Initiative on CLL (ERIC) International Meetings
Kostas Stamatopoulos
1:37
Progress in CLL diagnosis and treatment
Kanti Rai
2:36
Current knowledge of the TP53 mutation and its role in CLL
Jitka Malcikova
6:28
Prognostic markers and MRD in CLL
Robin Foà
1:49
The future of CLL: managing new toxicities and improved categorization
Daniel Catovsky
3:01
Cell-intrinsic biomarkers in CLL: focus on cytogenetics
Blanca Espinet
The content of VJHemOnc is intended for healthcare professionals